STRATA Skin Sciences (SSKN) IAccess Alpha Buyside Best Ideas Virtual Fall Conference 2024 summary

Business overview and strategy

• Focuses on dermatological autoimmune diseases with proprietary devices, primarily XTRAC and TheraClearX, targeting psoriasis, vitiligo, and acne.

• Employs a unique go-to-market model: devices are placed free with physicians, who pay per use, supported by comprehensive services including training, reimbursement support, and DTC marketing.

• Recurring revenue from domestic operations accounts for about two-thirds of total revenue, with international markets (notably China, South Korea, Japan, and the Middle East) comprising the rest.

• Over 900 domestic partner clinics are supported by in-house call centers and marketing, driving patient leads and clinic appointments.

• The company is majority-owned by insiders and a private equity fund, with a significant insider investment reflecting confidence in undervalued potential.

Financial performance and turnaround progress

• Revenue stabilization and gross margin expansion are underway, with margins rising from 52% to 58% year-over-year in Q2.

• Operating expenses have been reduced, moving the company close to net breakeven and generating cash.

• Insiders have provided additional capital to support the turnaround and growth initiatives.

• Gross margins are targeted to return to over 70% annually, as seen in previous years, with further improvement expected over the next few quarters.

• The business model's recurring revenue component is expected to drive self-sustaining growth and margin expansion.

Technology and clinical efficacy

• XTRAC and TheraClearX are supported by over 300 peer-reviewed clinical studies, demonstrating strong efficacy and safety.

• XTRAC is recommended as a first or second-line treatment for most psoriasis patients, offering high efficacy and lower costs for payers.

• Both devices enable providers to generate significant additional revenue through reimbursed, delegated procedures.

• TheraClearX, acquired in late 2022, targets the large adolescent acne market and leverages the same service model as XTRAC.

• The company supports clinics in obtaining insurance pre-authorization and reimbursement for treatments.